Deals in Depth: April 2011
Meda paid $420 million in cash for exclusive worldwide rights to Novartis' dermatitis cream Elidel. J&J's acquisition of orthopedic device company Synthes topped the acquisition list at $21.7 billion. The $1.6 billion in biopharma financing was outshone by Royalty Pharma's $487 million purchase of Cubicin and Lexiscan royalties. Similarly the one outlier device transaction - DJO's $300 million notes offering - represented 64% of the $471 million in device fundraising.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.